ArticleBMC infectious diseases2025
Extended spectrum beta-lactamase producing Escherichia coli encoding aminoglycoside and fluoroquinolone resistant genes in urinary tract infection patients in a tertiary hospital in Nigeria.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phenotype-First Diagnostic Framework for Tracking Fluoroquinolone Resistance inDiagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli causing urinary tract infections (UTIs) remains the most common bacterial infection diagnosed among outpatients as well as hospitalized patients. This study aimed to detect the extended-spectrum beta-lactamase-producing E. coli habouring aminoglycosides and fluoroquinolone-resistant genes in UTI patients. A total of 372 clean-catch midstream urine samples of patients with UTI attending Alex Ekwueme Federal University Teaching Hospital Abakaliki, Nigeria (AE-FUTHA) was collected. The collected urine samples were processed using standard microbiology and molecular methods to isolate and identify E. coli. Detection of ESBL-producing E. coli was performed using the double-disk synergy test. The ESBL-producing E. coli were subjected to antimicrobial susceptibility testing following the standard Kirby-Bauer disk diffusion method. PCR-specific primers were used to screen for the ESBL, aminoglycosides and fluoroquinolone-resistant genes. Out of the 372 urine samples collected, 84 (22.58%) distinct E. coli isolates were recovered, out of which 24 (28.57%) were ESBL positive. While all the isolates were resistant to amoxicillin/clavulanic acid 24 (100%), others were highly resistant to aztreonam and sulfamethoxazole/trimethoprim 22 (91.7%), ceftriaxone 21 (87.5%), ceftazidime and cefotaxime 16 (66.7%). Resistance to a fluoroquinolone, a ciprofloxacin was observed in 15 (62.5%). Out of the 24 ESBL-positive isolates, 12 were selected based on their resistance to both aminoglycosides and fluoroquinolones antibiotics used. These ESBL-producing E. coli encoded
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.